MCID: CHR417
MIFTS: 64

Chronic Graft Versus Host Disease

Categories: Rare diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

Summaries for Chronic Graft Versus Host Disease

NIH Rare Diseases : 53 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.  

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and hematopoietic stem cell transplantation. An important gene associated with Chronic Graft Versus Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Foscarnet and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are poor wound healing and intermittent generalized erythematous papular rash

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.4 IFNG IL10 IL1A
2 hematopoietic stem cell transplantation 31.9 IFNG IL10
3 erythema multiforme 30.6 CD79A IFNG
4 pure red-cell aplasia 30.4 ALB IL2RA
5 cervicitis 30.4 CD79A IL2RA
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IFNG IL10 TNFSF13B
7 acute graft versus host disease 30.3 IFNG IL10 IL2RA
8 chronic inflammatory demyelinating polyradiculoneuropathy 30.3 ALB IFNG
9 protein-losing enteropathy 30.2 ALB CD79A
10 aspergillosis 30.2 CD79A IFNG IL10
11 cytomegalovirus infection 30.1 IFNG IL10 IL2RA
12 hemophagocytic lymphohistiocytosis 30.0 IFNG IL10 IL2RA
13 polyradiculoneuropathy 30.0 ALB IFNG IL10
14 myeloma, multiple 29.7 ALB CD79A TNFSF13B
15 multiple sclerosis 29.7 IFNG IL10 IL2RA TNFSF13B
16 keratoconjunctivitis sicca 29.5 ALB CD79A IL10 IL1A
17 uveitis 29.5 IFNG IL10 IL1A IL2RA
18 psoriasis 29.1 IFNG IL10 IL1A MICA
19 autoimmune disease 28.8 CD79A IFNG IL10 IL2RA TNFSF13B
20 systemic lupus erythematosus 28.2 ALB CD79A IFNG IL10 IL2RA TNFSF13B
21 baylisascariasis 10.8 IFNG IL10
22 pericardial tuberculosis 10.7 IFNG IL10
23 tuberculoid leprosy 10.7 IFNG IL10
24 scabies 10.7 IL10 IL1A
25 buruli ulcer 10.7 IFNG IL10
26 chronic active epstein-barr virus infection 10.7 IFNG IL10
27 multicentric castleman disease 10.7 IFNG IL10
28 immunoglobulin a deficiency 1 10.7 CD79A IL10
29 primary systemic mycosis 10.7 IFNG IL10
30 cow milk allergy 10.7 CD79A IL10
31 poliomyelitis 10.7 IFNG IL10
32 hand, foot and mouth disease 10.7 IFNG IL10
33 neuroschistosomiasis 10.7 CD79A IFNG
34 peanut allergy 10.6 IFNG IL10
35 jaw cancer 10.6 IFNG IL1A
36 chronic follicular conjunctivitis 10.6 CD79A IL1A
37 strongyloidiasis 10.6 CD79A IFNG
38 eales disease 10.6 IFNG IL10
39 salivary gland disease 10.6 CD79A TNFSF13B
40 multidrug-resistant tuberculosis 10.6 IL10 IL1A
41 cryptococcal meningitis 10.6 IFNG TNFSF13B
42 microscopic colitis 10.6 CD79A IFNG
43 post-transplant lymphoproliferative disease 10.6 IL10 IL1A
44 congenital hypogammaglobulinemia 10.6 CD79A IL1A
45 spotted fever 10.6 IFNG IL10
46 primary thrombocytopenia 10.6 CD79A TNFSF13B
47 primary peritoneal carcinoma 10.5 IFNG IL10
48 vulvovaginal candidiasis 10.5 CD79A IFNG
49 posterior uveitis 10.5 IFNG IL2RA
50 cryptosporidiosis 10.5 CD79A IL1A

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

59 32 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 poor wound healing 59 32 hallmark (90%) Very frequent (99-80%) HP:0001058
2 intermittent generalized erythematous papular rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0007432
3 xerostomia 59 32 frequent (33%) Frequent (79-30%) HP:0000217
4 recurrent corneal erosions 59 32 frequent (33%) Frequent (79-30%) HP:0000495
5 photophobia 59 32 frequent (33%) Frequent (79-30%) HP:0000613
6 abnormality of skin pigmentation 59 32 frequent (33%) Frequent (79-30%) HP:0001000
7 keratoconjunctivitis sicca 59 32 frequent (33%) Frequent (79-30%) HP:0001097
8 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
9 onycholysis 59 32 frequent (33%) Frequent (79-30%) HP:0001806
10 bronchiectasis 59 32 frequent (33%) Frequent (79-30%) HP:0002110
11 recurrent infections 59 32 frequent (33%) Frequent (79-30%) HP:0002719
12 elevated hepatic transaminases 59 32 frequent (33%) Frequent (79-30%) HP:0002910
13 nail dystrophy 59 32 frequent (33%) Frequent (79-30%) HP:0008404
14 erythema 59 32 frequent (33%) Frequent (79-30%) HP:0010783
15 food intolerance 59 32 frequent (33%) Frequent (79-30%) HP:0012537
16 abnormality of the vagina 59 32 occasional (7.5%) Occasional (29-5%) HP:0000142
17 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
18 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
19 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
20 flexion contracture 59 32 occasional (7.5%) Occasional (29-5%) HP:0001371
21 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
22 phimosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001741
23 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
24 pancytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001876
25 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
26 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
27 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
28 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
29 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
30 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
31 esophageal stricture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002043
32 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
33 pneumothorax 59 32 occasional (7.5%) Occasional (29-5%) HP:0002107
34 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
35 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
36 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
37 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
38 esophageal ulceration 59 32 occasional (7.5%) Occasional (29-5%) HP:0004791
39 obstructive lung disease 59 32 occasional (7.5%) Occasional (29-5%) HP:0006536
40 bronchiolitis obliterans 59 32 occasional (7.5%) Occasional (29-5%) HP:0011946
41 entrapment neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012181
42 morphea 59 32 occasional (7.5%) Occasional (29-5%) HP:0012344
43 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
44 wheezing 59 32 occasional (7.5%) Occasional (29-5%) HP:0030828
45 fasciitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100537
46 urinary bladder inflammation 59 32 occasional (7.5%) Occasional (29-5%) HP:0100577
47 chest pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0100749
48 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037
49 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
50 thickened skin 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

26 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.74 MICA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.74 IL2RA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.74 IL2RA MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.74 IL2RA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.74 IL2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.74 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.74 IL2RA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.74 IL2RA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.74 IL2RA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 IL2RA MICA CD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.74 IL2RA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.74 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.74 IL2RA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 CD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 MICA IL2RA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.74 IL2RA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.74 IL2RA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.74 CD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.74 MICA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.74 IL2RA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 MICA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.74 IL2RA
23 Decreased caspase 3/7 activity GR00318-A 9.13 MICA TNFSF13B CD4

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 TNFSF13B CD79A IFNG IL10 CD36 IL1A
2 digestive/alimentary MP:0005381 9.88 IFNG ALB IL10 CD36 IL2RA CD4
3 homeostasis/metabolism MP:0005376 9.86 CD79A IFNG ALB IL10 CD36 IL1A
4 endocrine/exocrine gland MP:0005379 9.85 CD4 IFNG ALB IL10 CD36 IL2RA
5 immune system MP:0005387 9.76 TNFSF13B CD79A IFNG IL10 CD36 IL1A
6 liver/biliary system MP:0005370 9.35 CD79A IFNG ALB IL10 CD36
7 neoplasm MP:0002006 9.02 CD79A IFNG ALB IL10 IL1A

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4,Phase 2 63585-09-1, 4428-95-9 3415
2
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
3
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
4
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
5
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4 6253
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
8
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
9
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
10
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 128794-94-5 5281078
12
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 320-67-2 9444
13
Decitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2353-33-5 451668
14
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
15
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
16
Iron Approved Phase 4 7439-89-6 23925
17
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
18
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
19
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
20
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
22
Phosphonoacetic Acid Experimental Phase 4,Phase 2 4408-78-0 546
23
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
24 Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3 13909-09-6
25 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Reverse Transcriptase Inhibitors Phase 4,Phase 2
27 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Not Applicable
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cyclosporins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
39 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1
43 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 848)
# Name Status NCT ID Phase Drugs
1 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
2 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
3 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation Fro Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
4 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
5 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
6 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
7 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
8 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
9 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Recruiting NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
10 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
11 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
12 Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
13 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Unknown status NCT01295710 Phase 3
14 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
15 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
16 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
18 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
19 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
20 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
21 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
22 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
23 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
24 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
25 Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
26 Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
27 Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
28 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
29 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
30 Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD) Completed NCT00887263 Phase 3 Budesonide;Placebo
31 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
32 Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
33 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
34 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
35 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
36 Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation Completed NCT01530581 Phase 3
37 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
38 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
39 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
40 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
41 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
42 Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Completed NCT00412360 Phase 3 Cyclophosphamide;Fludarabine;Cyclosporine A;Mycophenolate Mofetil
43 Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Completed NCT00354120 Phase 2, Phase 3 Alentuzumab;Globulina antilinfocitaria
44 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
45 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
46 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
47 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
48 Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Recruiting NCT02291770 Phase 3
49 A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Recruiting NCT03474679 Phase 3 Ibrutinib
50 Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT Recruiting NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

41
T Cells, Bone, Bone Marrow, Myeloid, Skin, Lung, B Cells

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 733)
# Title Authors Year
1
HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature. ( 29721346 )
2018
2
Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. ( 29330402 )
2018
3
Full-body physical therapy evaluation for pre- and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. ( 29348574 )
2018
4
Topical vitamin D analog for chronic graft versus host disease of the skin. ( 29335622 )
2018
5
Novel management of vaginal chronic graft-versus-host disease causing haematometra and haematocolpos. ( 29705733 )
2018
6
Chronic graft versus host disease presenting as lichen planus pigmentosus. ( 29410549 )
2018
7
A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment. ( 29752810 )
2018
8
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease. ( 29740177 )
2018
9
Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. ( 29363541 )
2018
10
TGF-I^-Induced CD8<sup>+</sup>CD103<sup>+</sup>Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. ( 29441062 )
2018
11
Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: InvolvementA ofA Chronic Graft-Versus-Host Disease. ( 29854984 )
2018
12
Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. ( 29330403 )
2018
13
Total hysterectomy as hematocolpos treatment following bone marrow transplant. A rare complication of chronic graft-versus-host disease. ( 29329824 )
2018
14
Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. ( 29348127 )
2018
15
A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801. ( 29954931 )
2018
16
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease. ( 29670626 )
2018
17
Patient-reported outcomes and health status associated with chronic graft-versus-host disease. ( 29858386 )
2018
18
Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. ( 29664513 )
2018
19
Correction: Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. ( 29771974 )
2018
20
Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. ( 29959747 )
2018
21
Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. ( 29758393 )
2018
22
Griscelli Syndrome with Fibronodular Sclerodermatous Chronic Graft Versus Host Disease. ( 29398817 )
2018
23
Circulating monocyte subsets in human chronic graft-versus-host disease. ( 29728699 )
2018
24
B-cell targeting in chronic Graft-versus-Host disease. ( 29437591 )
2018
25
Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. ( 29788024 )
2018
26
Permanent alopecia as a manifestation of chronic graft-versus-host disease of the scalp: clinical, dermoscopic and histopathological observations. ( 29876958 )
2018
27
Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model. ( 29341972 )
2018
28
Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease. ( 29425517 )
2018
29
Chronic Graft-versus-Host Disease: A Long Road Ahead. ( 29353108 )
2018
30
Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. ( 29947972 )
2018
31
Overcoming human disagreement assessing erythematous lesion severity on 3D photos of chronic graft-versus-host disease. ( 29740182 )
2018
32
Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. ( 29692783 )
2018
33
Biomarkers in chronic graft-versus-host disease: quo vadis? ( 29367715 )
2018
34
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. ( 29367708 )
2018
35
Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. ( 29911695 )
2018
36
Palmoplantar lichen planus-like eruption in a patient with graft-versus-host disease: Is it rare presentation of chronic graft-versus-host disease? ( 29781533 )
2018
37
Pulmonary Injury and Chronic Graft-versus-Host Disease: Do We Miss the Signs and Symptoms? ( 28822829 )
2017
38
Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. ( 28934311 )
2017
39
Autologous artificial tears used for treatment of dry eye syndrome in patients with chronic graft versus host disease. ( 29162791 )
2017
40
Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. ( 28662983 )
2017
41
Oral verruciform xanthoma and erythroplakia associated with chronic graft-versus-host disease: a rare case report and review of the literature. ( 29183344 )
2017
42
Classification systems for chronic graft-versus-host disease. ( 27821503 )
2017
43
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. ( 27821504 )
2017
44
Efficacy and Safety of Topical Corticosteroids for Management of Oral Chronic Graft versus Host Disease. ( 28751912 )
2017
45
Low-dose anti-thymocyte globulin reduce severe acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. ( 28062916 )
2017
46
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. ( 28495794 )
2017
47
Cytokine mediators of chronic graft-versus-host disease. ( 28665299 )
2017
48
Musculoskeletal chronic graft versus host disease - A rare complication of allogeneic hematopoietic stem cell transplantation: A case report and review of its literature. ( 29404290 )
2017
49
High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. ( 28945764 )
2017
50
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. ( 29375566 )
2017

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 CD36 CD4 CD79A IFNG IL10 IL1A
2
Show member pathways
13.47 CD4 IFNG IL10 IL1A IL2RA TNFSF13B
3
Show member pathways
13.29 CD4 IFNG IL10 IL1A IL2RA TNFSF13B
4
Show member pathways
13.21 CD4 IL10 IL1A IL2RA TNFSF13B
5
Show member pathways
13.13 CD36 CD4 IFNG IL10 IL1A IL2RA
6
Show member pathways
13.09 CD4 IL10 IL1A IL2RA TNFSF13B
7
Show member pathways
12.6 CD79A IFNG IL1A IL2RA
8
Show member pathways
12.45 IFNG IL10 IL1A IL2RA
9
Show member pathways
12.44 CD4 IFNG IL10 IL1A IL2RA MICA
10 12.37 CD79A IFNG IL10 IL2RA TNFSF13B
11
Show member pathways
12.25 CD4 IFNG IL10 IL1A
12
Show member pathways
12.22 CD4 IFNG IL10 IL1A IL2RA
13
Show member pathways
12.09 CD4 IFNG IL10
14
Show member pathways
12.08 IFNG IL10 IL1A
15 12.05 IFNG IL10 IL1A
16 11.85 IFNG IL1A TNFSF13B
17 11.82 CD36 IL10 IL1A
18
Show member pathways
11.81 CD4 IFNG IL2RA
19
Show member pathways
11.81 CD4 IFNG IL10 IL1A IL2RA TNFSF13B
20 11.73 IFNG IL10 IL2RA
21 11.72 CD36 CD4 IL1A IL2RA
22 11.7 IFNG IL1A TNFSF13B
23 11.59 CD4 IFNG IL10
24 11.57 CD4 IFNG IL10 IL2RA
25 11.39 CD36 IFNG IL10
26 11.23 CD4 CD79A
27 11.22 CD4 IFNG IL10 IL2RA
28 11.21 IFNG IL10
29 11.2 IL10 IL1A
30 11.17 IFNG IL2RA
31 11.16 CD36 CD4 CD79A IFNG IL10 IL2RA
32 11.12 CD4 IFNG IL2RA
33
Show member pathways
11.11 IFNG IL2RA
34 11.05 IFNG IL10
35 10.91 IFNG IL1A
36 10.73 CD4 IFNG IL10 IL1A

GO Terms for Chronic Graft Versus Host Disease

Cellular components related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 CD36 CD4 IL2RA MICA
2 membrane raft GO:0045121 9.43 CD36 CD4 CD79A
3 external side of plasma membrane GO:0009897 9.26 CD36 CD4 CD79A IL2RA
4 extracellular space GO:0005615 9.17 ALB CD36 IFNG IL10 IL1A MICA

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.8 CD4 CD79A IL2RA TNFSF13B
2 regulation of signaling receptor activity GO:0010469 9.73 IFNG IL10 IL1A TNFSF13B
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 CD36 CD4 IL1A
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.63 CD36 CD4 IL1A
5 cytokine-mediated signaling pathway GO:0019221 9.55 CD36 CD4 IL10 IL1A IL2RA
6 B cell proliferation GO:0042100 9.52 CD79A IL10
7 positive regulation of cytokine secretion GO:0050715 9.51 IL10 IL1A
8 positive regulation of interleukin-12 production GO:0032735 9.48 CD36 IFNG
9 positive regulation of T cell proliferation GO:0042102 9.43 CD4 IL2RA TNFSF13B
10 regulation of regulatory T cell differentiation GO:0045589 9.4 IFNG IL2RA
11 negative regulation of growth of symbiont in host GO:0044130 9.37 CD36 IL10
12 cell surface receptor signaling pathway GO:0007166 9.35 CD36 CD4 CD79A IFNG IL2RA
13 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.32 CD4 IL1A
14 immune response GO:0006955 9.17 CD36 CD4 IFNG IL10 IL1A IL2RA

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IFNG IL10 IL1A TNFSF13B

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....